IGF-1 LR3

What Is IGF-1 LR3? Why It Is a Protein, Not a Peptide

UKPWritten and published by UK Peptides2 min readUpdated 4 cited sources

The short answer

IGF-1 LR3 is an engineered analogue of insulin-like growth factor 1: an 83-residue protein carrying a 13-residue N-terminal extension and an arginine substituted at position 3. Both modifications reduce binding to IGF binding proteins. It is a recombinant protein, not a synthesised peptide.

Key facts

Length
83 residues
Native IGF-1
70 residues, ~7.6 kDa
Modifications
13-residue N-extension; Arg at position 3
Purpose of both
Reduce IGF binding protein affinity
Disulfide bonds
Three
Produced by
Recombinant expression
UniProt (native)
P05019
WADA status
Prohibited at all times, class S2

What the name encodes

Long R3 IGF-1. Long refers to the thirteen extra residues added at the N-terminus. R3 refers to arginine replacing the native glutamate at position 3. Both changes serve one purpose: reducing the analogue's affinity for the IGF binding proteins that normally sequester circulating IGF-1.

Why that design exists

In circulation, the overwhelming majority of IGF-1 is not free. It is bound to IGF binding proteins, largely in a ternary complex with IGFBP-3 and the acid-labile subunit, as Baxter reviewed in Hormone Research in 1994. Bound IGF-1 cannot engage its receptor. An analogue that escapes that sequestration has a much larger free fraction at the same total concentration.

Research material referenced

IGF-1 LR3 1mg, third-party HPLC tested

Buy IGF-1 LR3 · £49.99

The design inversion worth noticing

Almost every other engineered compound in this catalogue does the opposite. Retatrutide and semaglutide add fatty acids to bind albumin. CJC-1295 with DAC binds albumin covalently. All of them add binding to extend duration. IGF-1 LR3 removes binding to increase availability. Same underlying bound-free equilibrium, engineered in opposite directions for different reasons.

Why it is a protein and not a peptide

At 83 residues with three disulfide bonds and a folded tertiary structure, this is a small protein. It is produced by recombinant expression in host cells rather than by stepwise chemical synthesis, and that difference runs through everything: what impurities exist, what a purity figure means, and what quality control has to test for.

Where it came from

Its established use is as a cell culture supplement, where resistance to binding proteins secreted by cultured cells makes it more consistently available than native IGF-1. That is a laboratory reagent application, and it is the context the compound was developed for.

Regulatory and prohibited status

IGF-1 LR3 holds no marketing authorisation anywhere. A licensed recombinant human IGF-1 does exist (mecasermin, marketed as Increlex), but that is native rhIGF-1 and a different molecule. IGF-1 and its analogues are on the WADA Prohibited List under class S2, prohibited at all times in and out of competition.

Frequently asked questions

What does LR3 stand for?

Long R3: a 13-residue N-terminal extension, and arginine substituted for glutamate at position 3.

Is it a peptide?

It is a small protein: 83 residues with three disulfide bonds and a folded structure, made recombinantly rather than synthesised.

Is it prohibited in sport?

Yes. IGF-1 and its analogues are on the WADA Prohibited List under class S2, prohibited at all times.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More IGF-1 LR3 articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.